iData Insights

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 27, 2016 16:14 IST

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015, provides an overview of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD)s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173374/peripheral-arterial-disease-pad-peripheral-vascular-disease-pvd-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173374/peripheral-arterial-disease-pad-peripheral-vascular-disease-pvd-pipeline-review-h2-2015

Table of Contents

Introduction 9

Global Markets Direct Report Coverage 9

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview 10

Therapeutics Development 11

Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview 11

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies 12

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Unknown Stage Products 17

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies 18

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development 21

Alvogen Korea 21

AnGes MG, Inc. 22

AstraZeneca Plc 23

Athersys, Inc. 24

Bayer AG 25

Betagenon AB 26

Cardiolynx AG 27

CardioVascular BioTherapeutics, Inc. 28

Celgene Corporation 29

Diffusion Pharmaceuticals LLC 30

DNAVEC Corporation 31

Hemostemix Ltd 32

Mesoblast Limited 33

miRagen Therapeutics, Inc. 34

Multi Gene Vascular Systems Ltd 35

Nuo Therapeutics, Inc. 36

Proteon Therapeutics, Inc. 37

Recardio GmbH 38

Resverlogix Corp. 39

Sagene Pharmaceuticals, Inc. 40

Stemedica Cell Technologies, Inc. 41

Symic Biomedical, Inc. 42

Theravasc, Inc. 43

ViroMed Co., Ltd. 44

Yuyu Pharma, Inc. 45

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment 46

Assessment by Monotherapy Products 46

Assessment by Combination Products 47

Assessment by Target 48

Assessment by Mechanism of Action 50

Assessment by Route of Administration 52

Assessment by Molecule Type 54

Drug Profiles 56

(cilostazol + organic nitrate) ER - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

ACP-01 - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

AEM-28 - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

ALD-301 - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Annexin A-5 - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

apabetalone - Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

beperminogene perplasmid - Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

CVBT-141C - Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

DVC1-0101 - Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

ELS-140 - Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease - Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

MGN-6114 - Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

MultiGeneAngio - Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

MultiStem - Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

O-304 - Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

PDA-002 - Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

REC-03 - Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Rejuveinix - Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

rivaroxaban - Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

sarpogrelate SR - Drug Profile 95

Product Description 95

Mechanism of Action 95

R&D Progress 95

SB-030 - Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

selegiline + Antiplatelet Drugs - Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

sodium nitrite SR - Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Stem Cell Therapy for Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease, Infectious Disease and Toxicology - Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

Synthetic Peptide to Inhibit PAI-1 for Cardiovascular Diseases and Oncology - Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

ticagrelor - Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

transcrocetinate sodium - Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

TXA-127 - Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

VM-202 - Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

vonapanitase - Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

YY-984 - Drug Profile 114

Product Description 114

Mechanism of Action 114

R&D Progress 114

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Recent Pipeline Updates 115

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects 160

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products 162

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones 163

Featured News & Press Releases 163

Oct 12, 2015: Proteon Therapeutics Announces Results from Phase 1 Study of Investigational Drug Vonapanitase in Patients with Symptomatic Peripheral Artery Disease Presented at TCT 2015 163

Aug 13, 2015: Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease 163

Feb 02, 2015: The Small molecule AMPK activator O304 acts as an oral PCSK9 inhibitor 164

Jan 08, 2015: Journal of Cardiovascular Pharmacology Publishes Positive Nonclinical Results of Proteon Therapeutics' PRT-201 in Peripheral Artery Disease 165

Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 165

Mar 17, 2014: AstraZeneca Announces Progress on Global PARTHENON Clinical Trial Program with BRILINTA in High-Risk Cardiovascular Disease Patient Populations in Advance of American College of Cardiology Scientific Session 166

Mar 05, 2013: Tarix Pharma's Peptide Technology Stimulates Revascularization Following Ischemia 168

Dec 06, 2012: Cytomedix Announces Landmark Bright Cell Therapy Study In Peripheral Arterial Disease 169

Oct 15, 2012: Proteon Therapeutics Initiates Patient Enrollment In Phase I Clinical Study Of PRT-201 In Patients Suffering From Peripheral Artery Disease 170

Aug 17, 2012: Anges Announces Publication of Long-Term Phase I/II Trial Data of Collategene In Medical Journal 170

Appendix 171

Methodology 171

Coverage 171

Secondary Research 171

Primary Research 171

Expert Panel Validation 171

Contact Us 171

Disclaimer 172

Read More http://www.idatainsights.com/reports-landing-page.php?id=173374/peripheral-arterial-disease-pad-peripheral-vascular-disease-pvd-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects